Ethical Issues in End-of-Life Care Indian Medical PG Practice Questions and MCQs
Practice Indian Medical PG questions for Ethical Issues in End-of-Life Care. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Ethical Issues in End-of-Life Care Indian Medical PG Question 1: Which of the following drugs should be given in a sustained-release oral dosage form?
- A. An anti-arrhythmic drug with a plasma half life of 10 seconds used for acute treatment of PSVT
- B. Anti inflammatory drugs with the plasma half life of 24 hours
- C. Hypnotic drugs with a plasma half life of 2 hours
- D. An antihypertensive with a plasma half-life of 3 hours (Correct Answer)
Ethical Issues in End-of-Life Care Explanation: *An anti-arrhythmic drug with a plasma half life of 10 seconds used for acute treatment of PSVT*
- An extremely short **half-life** (10 seconds) indicates a drug suitable for **rapid-onset, acute interventions**, where the effect is needed immediately and for a very brief duration, making sustained release impractical.
- Drugs like **adenosine**, used for acute PSVT, are given intravenously as a rapid bolus due to their ultra-short half-life, not in an oral sustained-release form.
*Anti inflammatory drugs with the plasma half life of 24 hours*
- A long **half-life** (24 hours) typically means the drug can be administered **once daily** to maintain therapeutic concentrations, rendering a sustained-release formulation unnecessary.
- Such drugs already provide **prolonged action** and do not benefit significantly from further extension of release.
*Hypnotic drugs with a plasma half life of 2 hours*
- While a 2-hour half-life for a hypnotic might suggest potential for sustained release to prolong sleep, the goal of hypnotics is often a **rapid onset and relatively short duration** to avoid hangover effects.
- Sustained release might cause **daytime sedation** and interfere with normal wakefulness, which is generally undesirable for this class of drugs.
***An antihypertensive with a plasma half-life of 3 hours***
- A short **half-life** (e.g., 3 hours) often necessitates frequent dosing to maintain therapeutic levels, making a **sustained-release formulation desirable** for patient compliance and consistent drug exposure.
- Sustained-release dosage forms are particularly useful for drugs requiring **long-term, stable plasma concentrations**, such as antihypertensives, to manage chronic conditions effectively.
Ethical Issues in End-of-Life Care Indian Medical PG Question 2: When a doctor shows gross absence of skill and care during treatment resulting in death of the patient is called:
- A. Malpractice
- B. Criminal negligence (Correct Answer)
- C. Misadventure
- D. Maloccurrence
Ethical Issues in End-of-Life Care Explanation: ***Criminal negligence***
- This involves a **gross deviation from the standard of care** by a medical professional, demonstrating a reckless disregard for the patient's well-being, directly leading to severe harm or death.
- Unlike malpractice, which can be civil, **criminal negligence** includes a higher burden of proof and carries legal penalties such as imprisonment.
*Malpractice*
- This refers to a medical professional's failure to exercise the **degree of care and skill** that a reasonably prudent and competent professional would exercise under similar circumstances.
- It usually results in **civil litigation**, seeking monetary damages for injuries caused by the negligence but does not necessarily imply criminal intent or gross deviation from care.
*Misadventure*
- This describes an **unforeseeable and unavoidable accident** or complication that occurs during medical treatment despite the healthcare provider acting within the standard of care.
- It implies an outcome that is neither the fault of the patient nor the doctor, and it does not involve any **negligence or lack of skill**.
*Maloccurrence*
- This term is often used interchangeably with "misadventure" and refers to an **unfavorable outcome** that occurs during medical treatment, despite the appropriate care being provided.
- It signifies an **unintended negative event** that is not due to negligence or a breach of duty by the medical professional.
Ethical Issues in End-of-Life Care Indian Medical PG Question 3: In acute left ventricular failure with pulmonary edema, which drug can be administered for immediate management?
- A. Morphine (Correct Answer)
- B. Amlodipine
- C. Epinephrine
- D. Propranolol
Ethical Issues in End-of-Life Care Explanation: ***Morphine***
- **Morphine** is a key drug in the **acute management of left ventricular failure with pulmonary edema**
- It provides **anxiolysis**, reduces **sympathetic drive**, and decreases **preload** through venodilation
- Reduces **oxygen demand** and **work of breathing** in acute decompensation
- Standard dose: **2-5 mg IV**, can be repeated as needed
- Caution needed for **respiratory depression** and **hypotension**, but benefits outweigh risks in severe pulmonary edema
*Propranolol*
- **Propranolol** is a **non-selective beta-blocker** that is **contraindicated in acute/decompensated heart failure**
- Beta-blockers **reduce contractility** and can worsen acute cardiac output
- While certain beta-blockers (carvedilol, metoprolol, bisoprolol) are used in **chronic stable heart failure**, propranolol is NOT a guideline-recommended agent for heart failure management
- In acute settings, beta-blockers would precipitate or worsen decompensation
*Amlodipine*
- **Amlodipine** is a **dihydropyridine calcium channel blocker** used for hypertension and angina
- **Not recommended in heart failure** as it can cause **negative inotropic effects** and peripheral edema
- Does not provide mortality benefit and may worsen outcomes in LV dysfunction
- Other vasodilators (nitrates, ACE inhibitors) are preferred
*Epinephrine*
- **Epinephrine** is a potent **catecholamine** with alpha and beta effects
- Increases **heart rate**, **contractility**, and **systemic vascular resistance**
- Would dramatically increase **myocardial oxygen demand** and **afterload** in LV failure
- Reserved for **cardiac arrest** or **cardiogenic shock requiring inotropic support**, not routine LV failure management
- Risk of **arrhythmias** and **ischemia**
Ethical Issues in End-of-Life Care Indian Medical PG Question 4: Which of the following options best describes a doctrine related to negligence in medical practice?
- A. Volenti non fit injuria
- B. Duty of care
- C. Res ipsa loquitur (Correct Answer)
- D. Respondeat superior
Ethical Issues in End-of-Life Care Explanation: ***Res ipsa loquitur***
- This doctrine, meaning "the thing speaks for itself," is applied when the injury would not have occurred without **negligence**, and the defendant was in **exclusive control** of the instrument causing the injury.
- It shifts the burden of proof to the defendant to show they were not negligent, often used in cases where direct evidence of negligence is scarce.
*Volenti non fit injuria*
- This doctrine means "to a willing person, no injury is done," implying that a person who knowingly and voluntarily exposes themselves to a risk cannot later sue for damages.
- It is a defense that argues the plaintiff consented to the harm, which is distinct from demonstrating the presence of negligence itself.
*Duty of care*
- This is a fundamental element of negligence, referring to the legal obligation of healthcare professionals to act reasonably and avoid causing harm to their patients.
- While essential for proving negligence, "duty of care" itself is not a doctrine that describes how negligence is established, but rather a *component* of it.
*Respondeat superior*
- This doctrine, meaning "let the master answer," holds employers liable for the negligent actions of their employees when those actions occur within the scope of employment.
- While relevant in medical malpractice cases involving hospital staff, it attributes liability to the employer rather than defining the elements of negligence itself.
Ethical Issues in End-of-Life Care Indian Medical PG Question 5: India is a country with different cultures and diverse languages. Which steps should a physician take to address the patient for better outcomes?
1. Insist on good communication
2. Insist on communication only via an interpreter
3. Treat them regardless of their cultural perceptions
4. The physician should consider the patient's religion and cultural perception
Select the correct combination:
- A. 1,4 (Correct Answer)
- B. 1,2
- C. 2,3
- D. 3,4
Ethical Issues in End-of-Life Care Explanation: ***1,4***
- **Good communication** is paramount in healthcare, especially in a diverse country like India, to ensure **patient understanding**, **adherence** to treatment plans, and overall patient satisfaction.
- Considering a patient's **religion and cultural perceptions** allows the physician to tailor treatment and communication in a sensitive and **respectful manner**, fostering trust and better **health outcomes**.
*1,2*
- While good communication (1) is vital, **insisting solely on an interpreter** (2) may not always be feasible or necessary, particularly if the physician and patient share a common language or if the patient prefers direct communication. This can also disrupt the flow of rapport building.
- **Over-reliance on interpreters** can sometimes lead to misinterpretations or loss of non-verbal cues if the interpreter is not trained in medical interpretation.
*2,3*
- **Insisting only on an interpreter** (2) can be restrictive and may compromise direct patient-physician rapport, as discussed above.
- **Treating patients regardless of their cultural perceptions** (3) is an ethnocentric approach that can lead to mistrust, non-adherence, and ultimately **poor health outcomes** as it disregards the patient's beliefs and values regarding health and illness.
*3,4*
- **Treating patients regardless of their cultural perceptions** (3) can result in a lack of understanding and non-adherence if the treatment conflicts with the patient's deeply held beliefs.
- While considering religion and cultural perception (4) is crucial, this option includes an incorrect approach (3) that can undermine patient care.
Ethical Issues in End-of-Life Care Indian Medical PG Question 6: Declaration of Oslo deals with:
- A. Therapeutic abortion (Correct Answer)
- B. Human experiments
- C. Right to death
- D. Organ donation
Ethical Issues in End-of-Life Care Explanation: ***Therapeutic abortion***
- The **Declaration of Oslo** was adopted by the World Medical Association (WMA) in 1970 to address the ethical considerations surrounding **therapeutic abortion**.
- It provides guidelines for physicians when faced with a mother's request for the **termination of pregnancy**, particularly concerning the physician's right to *conscientious objection* and the necessity of referral to another qualified medical practitioner.
*Right to death*
- This concept, often associated with debates around **euthanasia** or physician-assisted suicide, is not the primary focus of the Declaration of Oslo.
- Ethical guidelines on the right to death are typically covered by other declarations and policies, such as the WMA's statement on **euthanasia and physician-assisted suicide**.
*Human experiments*
- **Human experimentation** is primarily addressed by the **Declaration of Helsinki**, another key ethical document by the World Medical Association.
- The Declaration of Helsinki focuses on ethical principles for medical research involving human subjects, including informed consent and protection of vulnerable populations.
*Organ donation*
- **Organ donation** is an ethical issue addressed by various national laws and international guidelines, but it is not the subject of the **Declaration of Oslo**.
- Ethical considerations in organ donation often involve donor consent, organ allocation, and preventing commercialization.
Ethical Issues in End-of-Life Care Indian Medical PG Question 7: A 68-year-old man with terminal lung cancer develops confusion, myoclonus, and hallucinations after being on high-dose morphine (240 mg/day oral) for 2 weeks. His renal function shows creatinine 2.8 mg/dL. What is the most appropriate management considering the pathophysiology?
- A. Continue morphine but add naloxone infusion
- B. Add haloperidol for delirium and continue morphine
- C. Switch to fentanyl as it has no active metabolites and dose adjust for renal function (Correct Answer)
- D. Stop all opioids and use only adjuvant analgesics
Ethical Issues in End-of-Life Care Explanation: ***Switch to fentanyl as it has no active metabolites and dose adjust for renal function***
- The patient is experiencing **opioid-induced neurotoxicity (OIN)** due to the accumulation of morphine metabolites, specifically **Morphine-3-glucuronide (M3G)** and **Morphine-6-glucuronide (M6G)**, which are cleared renally.
- **Fentanyl** is the preferred opioid in renal impairment because it has no clinically significant active metabolites and does not undergo significant renal excretion [1].
*Continue morphine but add naloxone infusion*
- Adding **naloxone** would reverse the analgesic effects and likely precipitate an acute **withdrawal syndrome** or uncontrolled cancer pain.
- This does not address the underlying cause, which is the accumulation of **neuroexcitatory metabolites** in the setting of renal failure.
*Add haloperidol for delirium and continue morphine*
- **Haloperidol** may mask the symptoms of delirium but does not stop the progression of **myoclonus** or neurotoxicity caused by toxic metabolites.
- Continuing morphine in a patient with a **creatinine of 2.8 mg/dL** will lead to further metabolite accumulation and potential seizures.
*Stop all opioids and use only adjuvant analgesics*
- Abruptly stopping opioids in a patient on a high dose (240 mg/day) will lead to severe **withdrawal** and a massive **pain crisis**.
- Terminal lung cancer pain requires effective opioid management; switching to a safer agent (opioid rotation) is the standard of care rather than complete discontinuation [1].
Ethical Issues in End-of-Life Care Indian Medical PG Question 8: A 62-year-old woman with advanced ovarian cancer has been on oral morphine 90 mg BD for 3 months. She now reports reduced pain relief despite increasing doses, but experiences severe pain at specific sites of bone metastases. What is the best management strategy?
- A. Add ketamine infusion for opioid resistance
- B. Switch to fentanyl patch and continue dose escalation
- C. Add gabapentin and consider palliative radiotherapy to metastatic sites (Correct Answer)
- D. Rotate to hydromorphone at equianalgesic dose
Ethical Issues in End-of-Life Care Explanation: ***Add gabapentin and consider palliative radiotherapy to metastatic sites***
- Bone metastases often cause **neuropathic pain** and inflammatory response; adding a **gabapentinoid** treats the nerve-related component that opioids may not fully cover [1].
- **Palliative radiotherapy** is highly effective for localized bone pain, often allowing for **reduced opioid requirements** and improved quality of life.
*Add ketamine infusion for opioid resistance*
- While **ketamine** is an NMDA antagonist used for refractory pain, it is generally reserved for specialists when common adjuncts and localized treatments fail.
- It is a more invasive and complex intervention compared to **radiotherapy** and oral adjuvants like **gabapentin** for focal bone pain.
*Switch to fentanyl patch and continue dose escalation*
- Increasing the dose of a different opioid (dose escalation) is unlikely to resolve **opioid-insensitive** bone pain and may increase the risk of **opioid-induced hyperalgesia** [2].
- Transdermal **fentanyl** is more suitable for stable pain control and does not address the localized, metastatic nature of the patient's pain [1].
*Rotate to hydromorphone at equianalgesic dose*
- **Opioid rotation** to hydromorphone is helpful if the patient is experiencing side effects, but it does not address the underlying pathology of **bone metastases** [1].
- Rotation alone does not provide the specific **neuropathic** or **anti-tumor** benefits offered by the combination of gabapentin and radiotherapy.
Ethical Issues in End-of-Life Care Indian Medical PG Question 9: A 55-year-old man with terminal esophageal cancer develops respiratory secretions causing death rattle. Despite positioning and suctioning, the symptom persists. Which medication would be most appropriate and why?
- A. Morphine - reduces respiratory drive and secretions
- B. Hyoscine butylbromide - antimuscarinic action reduces secretions without sedation (Correct Answer)
- C. Midazolam - sedates patient reducing awareness of secretions
- D. Furosemide - reduces fluid overload causing secretions
Ethical Issues in End-of-Life Care Explanation: Hyoscine butylbromide - antimuscarinic action reduces secretions without sedation
- **Hyoscine butylbromide** is the preferred medication for the **death rattle** because its **antimuscarinic properties** effectively dry up salivary and bronchial secretions.
- Unlike hyoscine hydrobromide, it does not cross the **blood-brain barrier**, meaning it reduces secretions with minimal risk of **sedation** or **delirium**.
*Morphine - reduces respiratory drive and secretions*
- While **morphine** is excellent for managing **dyspnea** and pain at the end of life, it does not possess **antisecretory** properties to manage a death rattle [1].
- Overuse of opioids for secretions can lead to unnecessary **respiratory depression** or decreased level of consciousness without fixing the noisy breathing.
*Midazolam - sedates patient reducing awareness of secretions*
- **Midazolam** is a benzodiazepine used for **terminal agitation** or anxiety but does not affect the production of **respiratory secretions**.
- Although it might reduce patient awareness, it does not address the **audible noise** which is often distressing for the family members observing the patient [2].
*Furosemide - reduces fluid overload causing secretions*
- **Furosemide** is indicated for **pulmonary edema** caused by congestive heart failure, not for the terminal accumulation of oropharyngeal secretions.
- Using diuretics in a terminal patient with a death rattle is generally **ineffective** as the noise is caused by pooled saliva rather than **systemic fluid overload**.
Ethical Issues in End-of-Life Care Indian Medical PG Question 10: A 70-year-old man with advanced pancreatic cancer on sustained-release morphine 60 mg BD develops breakthrough pain 3-4 times daily. His pain is otherwise well controlled. What should be the dose of immediate-release morphine for breakthrough pain?
- A. 6 mg
- B. 12 mg (Correct Answer)
- C. 20 mg
- D. 30 mg
Ethical Issues in End-of-Life Care Explanation: ***12 mg***
- The standard dose for **breakthrough pain** is calculated as **one-sixth (approx 16%) or 10%** of the **total daily dose** (TDD) of the regular opioid.
- Since the patient takes 60 mg twice daily, the **TDD is 120 mg**; 10% of 120 mg is **12 mg**, providing a safe and effective immediate-release dose [1].
*6 mg*
- This dose represents only **5%** of the TDD, which is typically insufficient to manage moderate-to-severe **breakthrough pain**.
- Using a dose this low may lead to **inadequate analgesia** and multiple repeat doses, which is not clinically optimal [1].
*20 mg*
- This dose exceeds the standard **10-16% recommendation** for breakthrough medication in a patient whose pain is otherwise and normally **well controlled**.
- High breakthrough doses relative to the TDD increase the risk of **opioid toxicity**, such as excessive sedation or **respiratory depression**.
*30 mg*
- This is **25%** of the daily dose, which is significantly higher than the recommended safety margin for **palliative care** breakthrough protocols [1].
- Such a high dose would typically only be considered if the **background pain** was also poorly controlled and the oral dose was being titrated upward.
More Ethical Issues in End-of-Life Care Indian Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
